ERBB2 and breast cancer: Currently based on the 2018 guideline, breast cancers are classified as either HER2-positive (IHC3+ or 2+ with gene amplification by ISH) or HER2-negative (IHC 0+ or 1+ or 2+ without ISH amplification).